iBio, Inc. — Form 10-Q Summary
Business Context and Reporting Period
iBio, Inc. is a biotechnology company commercializing plant-based protein expression technologies, including the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement. The company also develops selected biopharmaceutical candidates and pursues licensing, collaboration, and partnering opportunities.
This report covers the quarter and six months ended December 31, 2013. The financial statements are unaudited. iBio was a smaller reporting company with 64.4 million common shares outstanding at December 31, 2013 and 65.6 million shares outstanding as of February 13, 2014.
Financial Performance and Position
| Metric | Three Months Ended December 31 | Six Months Ended December 31 |
|---|---|---|
| Revenue | $0.0 million in 2013 and 2012 | $0.0 million in 2013 versus $0.4 million in 2012 |
| Operating loss | $1.6 million versus $1.7 million | $1.4 million versus $3.5 million |
| Net loss | $1.6 million versus $1.1 million | $1.2 million versus $3.1 million |
| Loss per share | $0.03 versus $0.02 | $0.02 versus $0.07 |
| Operating cash flow | Not provided for the quarter | $(2.2) million versus $(2.7) million |
Six-month operating expenses were $1.4 million, compared with $3.9 million in the prior-year period. The reduction included nonrecurring credits from the Fraunhofer settlement: $1.04 million to research and development, $0.7 million to general and administrative expense, and $0.12 million to interest expense. Excluding these credits, management reported research and development spending of approximately $1.1 million and general and administrative spending of approximately $2.0 million.
Cash was $5.7 million at December 31, 2013, compared with $4.4 million at June 30, 2013. Total assets were $9.6 million, total liabilities were $1.7 million, and stockholders’ equity was $8.0 million. The filing does not report funded debt; liabilities consisted primarily of accounts payable and accrued expenses.
Investing activities used $0.1 million, primarily for intangible assets. Financing activities provided $3.6 million, consisting primarily of $3.1 million from warrant exercises and $0.5 million from a private placement, partially offset by $0.03 million of capital-raising costs.
Material Changes Versus the Prior Comparable Period
- Revenue declined to zero for the six-month period from $0.4 million, as work on the FioCruz yellow fever vaccine program awaited Brazilian government approval of a contract amendment.
- Six-month net loss improved to $1.2 million from $3.1 million, principally because of the Fraunhofer settlement credits and lower operating spending. The quarterly net loss increased to $1.6 million from $1.1 million because the prior-year quarter included $0.6 million of non-cash warrant derivative income.
- Research and development expense declined to $1.1 million before settlement credits, primarily because of lower Fraunhofer-related activity and delays in the FioCruz program.
- The company issued 7.75 million shares through a warrant exercise inducement and received approximately $3.1 million. It also sold 1.2 million shares in a private placement at $0.40 per share for approximately $0.5 million of net proceeds; those shares were classified as common stock to be issued at December 31.
- Outstanding warrants declined from 25.4 million at June 30, 2013 to 12.6 million at December 31, 2013 because of exercises and expirations. Approximately 5.0 million August 2008 warrants expired in August 2013, eliminating the related derivative liability.
- Authorized common shares increased from 100 million to 175 million, and the equity incentive plan was increased from 10 million to 15 million reserved shares.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management’s near-term objectives are to establish additional commercial, government, and nonprofit licensing or collaboration arrangements and to advance selected product candidates toward clinical development. The company expects to rely on licensees and partners to help fund development and commercialization.
Management stated that cash on hand at December 31, 2013 was expected to support activities through the quarter ending December 31, 2014. However, the filing states that the company’s recurring losses, negative operating cash flow, limited cash resources, and dependence on additional financing raise substantial doubt about its ability to continue as a going concern. Future funding may come from cash on hand, additional equity or other securities, and licensing or collaboration proceeds. Additional equity financing could materially dilute existing stockholders, and financing may not be available on favorable terms or at all.
The September 2013 Fraunhofer settlement released approximately $2.9 million of liabilities and replaced three $1.0 million guaranteed payments with a requirement to engage Fraunhofer for at least $3.0 million of research and development work by December 31, 2015. The filing initially reported approximately $1.6 million of related agreements, but also disclosed termination of a $1.5 million agreement effective January 31, 2014; after termination, approximately $0.6 million had been incurred toward the commitment. The agreement extended the technology transfer arrangement through December 31, 2015 and reduced certain royalty rates from 15% to 10%.
Fraunhofer remained the company’s most significant vendor, with approximately $1.0 million in accounts payable and $0.2 million in accrued expenses at December 31, 2013. In January 2014, iBio acquired exclusive worldwide rights to certain fibrosis-related patents from a U.S. university and undertook license fees, maintenance fees, patent-cost reimbursements, milestones, royalties, and development diligence obligations.
Other risks include the absence of recurring revenue, dependence on successful technology licensing and product development, regulatory and clinical uncertainties, intellectual-property risks, reliance on significant vendors and related parties, potential dilution, and the possibility of delaying or discontinuing programs or ceasing operations if funding is unavailable.
Important Facts for Investors to Verify
- Whether the FioCruz contract amendment was approved and whether the program resumed generating revenue after the reporting date.
- The company’s actual cash runway and subsequent financing activity, given the going-concern uncertainty and continuing operating losses.
- Progress toward the $3.0 million Fraunhofer research commitment and the effect of the terminated $1.5 million research services agreement.
- Potential dilution from approximately 12.6 million outstanding warrants, approximately 8.7 million stock options, and additional authorized shares.
- Terms, costs, milestones, and development status of the January 2014 fibrosis patent license and related project agreement.
- Whether future licensing, collaboration, or product-development activities produce material revenue, since the filing reports no revenue for the current quarter or six-month period.